Observational studyCancer control : journal of the Moffitt Cancer Center
Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer.
Observational study in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Tumor Cell-Derived Exosomal miR-191-5p Activates M2-Subtype Macrophages Through SOCS3 to Facilitate Breast Cancer.Molecular biotechnology · 2024Article
- Circ-ITCH inhibits bladder cancer progression through miR-184/FOXO3 axis.American journal of translational research · 2024Article
- Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.Frontiers in oncology · 2023Review
- The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer.Journal of personalized medicine · 2022Review
- Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.Digestive diseases and sciences · 2022Article
- Long noncoding RNA regulatory factor X3- antisense RNA 1 promotes non-small cell lung cancer via the microRNA-577/signal transducer and activator of transcription 3 axis.Bioengineered · 2022Article
- circCNN2 Accelerates Cell Proliferation and Invasion in Lung Squamous Cell Carcinoma via Regulating miR-184/E2F1 and Activating MAPK Signaling Pathway.Disease markers · 2022Article
Corrections and comments
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to determine the diagnosis and prediction value of serum miR-184 and miR-191 levels in patients with non-small-cell lung cancer (NSCLC).
methodsOne hundred patients with NSCLC were enrolled (NSCLC group) and treated with gefitinib. In addition, 59 pneumonia cases (pneumonia group) and 51 healthy cases in the corresponding period (normal group) were included. Serum miR-184 and miR-191 expressions were detected by real-time quantitative polymerase chain reaction. Furthermore, the relationships between serum miR-184 and miR-191 expressions and clinicopathological parameters were analyzed. The use of serum miR-184 and miR-191 levels in the diagnosis of NSCLC and the prediction of treatment effectiveness and 3-year overall survival (OS) were assessed by the receiver operating characteristic curve. Hazard factors affecting the efficacy of treatment in patients with NSCLC were determined by logistic regression.
resultsThe serum levels of miR-184 in the NSCLC group were significantly lower than those in the pneumonia group and normal group, whereas miR-191 expression was significantly higher in the NSCLC group. Serum miR-184 and miR-191 levels were closely correlated with smoking history, the tumor node metastasis (TNM) stage, and the degree of pathological differentiation. The area under curve (AUC) of serum miR-184 combined with miR-191 in the diagnosis of patients in the NSCLC group and normal group, NSCLC group and pneumonia group, and the efficacy of treatment in patients with NSCLC was 0.925, 0.929, and 0.916, respectively. The AUC of serum miR-184 and miR-191 for the 3-year OS in patients with NSCLC was 0.869 and 0.879, respectively. Smoking history, the degree of pathological differentiation, local treatment, miR-184, and miR-191 were independent risk factors that affected treatment efficacy.
conclusionSerum miR-184 and miR-191 levels can potentially be used as molecular markers to diagnose and predict the curative effect of treatment in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.